Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Sets One-Month Target For Post-Marketing Requirement Discussions In Final Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry wanted FDA to impose a detailed set of internal requirements on itself before imposing PMRs, but in final guidance on the subject the agency does not do so.

You may also be interested in...



Merck’s Postmarketing Study Delays Prompt FDA To Unsheathe New Enforcement Power

Januvia and Janumet are misbranded, FDA tells Merck in a warning letter noting that rodent safety studies for the sitagliptin diabetes drugs were 20 months behind schedule. The letter marks the first time FDA has used its FDAAA powers to take enforcement action against a pharma company for such a delay.

FDAAA Post-Marketing Requirements Growing As Commitments Decline

Safety studies imposed under FDA Amendments Act authorities are a growing portion of sponsors’ post-approval study burden, while post-marketing commitments are declining, according to the latest FDA annual report on the status of post-marketing requirements and commitments.

FDAAA Post-Marketing Requirements Growing As Commitments Decline

Safety studies imposed under FDA Amendments Act authorities are a growing portion of sponsors’ post-approval study burden, while post-marketing commitments are declining, according to the latest FDA annual report on the status of post-marketing requirements and commitments.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072074

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel